Skip to main content

Table 1 Characteristics of CKD and non-CKD participants in NHANES 1999-2004

From: Adiposity measures, lean body mass, physical activity and mortality: NHANES 1999–2004

Variable CKD Non-CKD P-value**
(N = 2153) (N = 9433)
Age, years (mean ± SE) 60.7 (0.7) 43.9 (0.3) <0.001
Male gender, % (SE) 43.1 (1.0) 50.6 (0.4) <0.001
Race, % (SE)    0.004
  Non-Hispanic White 71.9 (2.1) 72.4 (1.6)  
  Non-Hispanic Black 10.8 (1.2) 9.9 (0.9)  
  Mexican American 5.6 (1.0) 7.6 (0.9)  
  Other Hispanic 5.8 (1.4) 5.8 (1.1)  
  Other 5.8 (1.0) 4.2 (0.4)  
Smoking, % (SE) 18.7 (1.1) 25.6 (0.8) <0.001
Income, % (SE)    <0.001
  Missing 11.0 (1.0) 9.0 (0.6)  
  <20,000 26.3 (1.8) 15.0 (0.8)  
  20,000-45,000 30.1 (1.4) 26.5 (1.0)  
  45,000-75,000 18.4 (1.6) 23.4 (0.8)  
  > = 75,000 14.2 (1.5) 26.1 (1.4)  
BMI (mean ± SE) 29.2 (0.3) 28.1 (0.1) <0.001
Waist circumference (cm) (mean ± SE) 101.1 (0.6) 96.1 (0.3) <0.001
Total fat kg (mean ± SE)* 30.3 (0.4) 28.1 (0.2) <0.001
Total lean mass excluding BMC kg (mean ± SE)* 49.1 (0.4) 51.2 (0.2) <0.001
Percent body fat (mean ± SE)* 36.7 (0.2) 33.8 (0.1) <0.001
eGFR, ml/min/1.73 m2 (mean ± SE) 72.9 (0.9) 96.8 (0.4) <0.001
UACR (mg/g) (mean ± SE) 154.4 (15.4) 7.1 (0.08) <0.001
C-reactive protein (mg/dL) 0.59 (0.03) 0.39 (0.009) <0.001
Hypertension (SBP >140 or DBP >90 mm Hg) or use of antihypertensives 62.4 (1.6) 25.2 (0.8) <0.001
Diabetes 20.4 (1.4) 4.6 (0.2) <0.001
Hyperlipidemia 67.9 (1.5) 52.8 (0.8) <0.001
Liver condition 3.7 (0.5) 3.1 (0.2) 0.07
Cancer,% (SE) 16.1 (1.1) 6.6 (0.3) <0.001
Physical activity,% (SE)    <0.001
  LTPA <450 METS/week 67.0 (1.7) 53.7 (1.1)  
  LTPA 450–749.9 METS/week 8.7 (0.8) 9.1 (0.4)  
  LTPA ≥750 METS/week 24.3 (1.5) 37.2 (1.0)  
Sodium intake mg (mean ± SE)*** 3011 (45) 3549 (30) <0.001
  1. *Means and standard errors from survey means on each of the 5 imputations analyzed using procmianalyze.
  2. **Rao-Scott Chi-square test for categorical variables and t-test for continuous variables.
  3. ***Sodium available for 2035 and 8095 CKD and non CKD participants respectively.